AnaptysBio (ANAB) Stock Forecast & Price Target

Compare

606 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ANAB Analyst Ratings

Strong Buy

8 Buy

2 Hold

0 Sell

Based on 10 analysts giving stock ratings to

AnaptysBio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ANAB Stock 12 Month Forecast

Average Price Target

$51.29

▲(71.71% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is $51.29 with a high forecast of $90.00 and a low forecast of $20.00. The average price target represents a 71.71% change from the last price of $29.87.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","91":"$91","31.75":"$31.8","51.5":"$51.5","71.25":"$71.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,31.75,51.5,71.25,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.97,36.433846153846154,40.89769230769231,45.36153846153846,49.825384615384614,54.28923076923077,58.75307692307692,63.216923076923074,67.68076923076923,72.14461538461538,76.60846153846154,81.07230769230769,85.53615384615384,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.97,33.456153846153846,34.94230769230769,36.428461538461534,37.91461538461538,39.40076923076923,40.886923076923075,42.37307692307692,43.85923076923077,45.34538461538462,46.83153846153846,48.31769230769231,49.80384615384615,{"y":51.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.97,31.049230769230768,30.128461538461536,29.207692307692305,28.286923076923078,27.366153846153846,26.445384615384615,25.524615384615384,24.603846153846153,23.683076923076925,22.762307692307694,21.841538461538462,20.92076923076923,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.81,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.86,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$90.00

Average Price Target$51.29

Lowest Price Target$20.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Risinger

Leerink Partners

$32→$37

Buy

23.87%

Upside

Reiterated

10/01/25

Joon Lee

Truist Financial

―

Hold

―

Reiterated

09/30/25

AnaptysBio (ANAB) Gets a Hold from Truist Financial

Yasmeen Rahimi

Piper Sandler

$57

Buy

90.83%

Upside

Reiterated

09/30/25

Piper Sandler Remains a Buy on AnaptysBio (ANAB)

Yatin Suneja

Guggenheim

$90

Buy

201.31%

Upside

Reiterated

09/30/25

Guggenheim Sticks to Their Buy Rating for AnaptysBio (ANAB)Guggenheim analyst Yatin Suneja reiterated a Buy rating and $90.00 price target on AnaptysBio (NASDAQ: ANAB).

Emily Bodnar

H.C. Wainwright

$38→$59

Buy

97.52%

Upside

Reiterated

09/30/25

AnaptysBio price target raised to $59 from $38 at H.C. WainwrightAnaptysBio price target raised to $59 from $38 at H.C. Wainwright

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

09/29/25

Strategic Split and Promising Pipeline: AnaptysBio's Path to Growth and Value Maximization

David Nierengarten

Wedbush

$45

Buy

50.65%

Upside

Reiterated

09/16/25

Wedbush Sticks to Its Buy Rating for AnaptysBio (ANAB)

Derek Archila

Wells Fargo

$51

Buy

70.74%

Upside

Reiterated

09/04/25

Analysts Are Bullish on These Healthcare Stocks: Senseonics Holdings (SENS), AnaptysBio (ANAB)We thought mgmt sounded positive on rosnilimab's chances in UC (data in 4Q25) and floor value for Jemperli. Risk/reward remains skewed to the upside in our view.

Eliana Merle

UBS

$18→$20

Hold

-33.04%

Downside

Reiterated

08/12/25

AnaptysBio price target raised to $20 from $18 at UBSAnaptysBio price target raised to $20 from $18 at UBS

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/06/25

AnaptysBio: Promising Pipeline and Strategic Developments Justify Buy Rating

Alex Thompson CFA

Stifel Nicolaus

$55

Buy

84.13%

Upside

Reiterated

06/04/25

Stifel Nicolaus Remains a Buy on AnaptysBio (ANAB)

Andy Chen

Wolfe Research

$25

Buy

-16.30%

Downside

Reiterated

05/21/25

Wolfe Research: Bullish long-term on ANABWolfe Research analyst Andy Chen reiterated an Outperform rating and $25.00 price target on AnaptysBio (NASDAQ: ANAB).

Julian Harrison

BTIG

―

Hold

―

Downgraded

12/02/24

AnaptysBio downgraded to Neutral from Buy at BTIGAnaptysBio downgraded to Neutral from Buy at BTIG

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Risinger

Leerink Partners

$32→$37

Buy

23.87%

Upside

Reiterated

10/01/25

Joon Lee

Truist Financial

―

Hold

―

Reiterated

09/30/25

AnaptysBio (ANAB) Gets a Hold from Truist Financial

Yasmeen Rahimi

Piper Sandler

$57

Buy

90.83%

Upside

Reiterated

09/30/25

Piper Sandler Remains a Buy on AnaptysBio (ANAB)

Yatin Suneja

Guggenheim

$90

Buy

201.31%

Upside

Reiterated

09/30/25

Guggenheim Sticks to Their Buy Rating for AnaptysBio (ANAB)Guggenheim analyst Yatin Suneja reiterated a Buy rating and $90.00 price target on AnaptysBio (NASDAQ: ANAB).

Emily Bodnar

H.C. Wainwright

$38→$59

Buy

97.52%

Upside

Reiterated

09/30/25

AnaptysBio price target raised to $59 from $38 at H.C. WainwrightAnaptysBio price target raised to $59 from $38 at H.C. Wainwright

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

09/29/25

Strategic Split and Promising Pipeline: AnaptysBio's Path to Growth and Value Maximization

David Nierengarten

Wedbush

$45

Buy

50.65%

Upside

Reiterated

09/16/25

Wedbush Sticks to Its Buy Rating for AnaptysBio (ANAB)

Derek Archila

Wells Fargo

$51

Buy

70.74%

Upside

Reiterated

09/04/25

Eliana Merle

UBS

$18→$20

Hold

-33.04%

Downside

Reiterated

08/12/25

AnaptysBio price target raised to $20 from $18 at UBSAnaptysBio price target raised to $20 from $18 at UBS

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/06/25

AnaptysBio: Promising Pipeline and Strategic Developments Justify Buy Rating

Alex Thompson CFA

Stifel Nicolaus

$55

Buy

84.13%

Upside

Reiterated

06/04/25

Stifel Nicolaus Remains a Buy on AnaptysBio (ANAB)

Andy Chen

Wolfe Research

$25

Buy

-16.30%

Downside

Reiterated

05/21/25

Wolfe Research: Bullish long-term on ANABWolfe Research analyst Andy Chen reiterated an Outperform rating and $25.00 price target on AnaptysBio (NASDAQ: ANAB).

Julian Harrison

BTIG

―

Hold

―

Downgraded

12/02/24

AnaptysBio downgraded to Neutral from Buy at BTIGAnaptysBio downgraded to Neutral from Buy at BTIG

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AnaptysBio

1 Month

xxx

Success Rate

12/15 ratings generated profit

Average Return

+9.17%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +9.17% per trade.

3 Months

xxx

Success Rate

9/13 ratings generated profit

Average Return

+11.42%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +11.42% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

14/18 ratings generated profit

Average Return

+19.65%

reiterated a buy rating 10 days ago

Copying Anupam Rama's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +19.65% per trade.

2 Years

xxx

Success Rate

12/13 ratings generated profit

Average Return

+45.35%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +45.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANAB Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ANAB has received 16 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. ANAB average Analyst price target in the past 3 months is 51.29.

Each month's total comprises the sum of three months' worth of ratings.

ANAB Financial Forecast

ANAB Earnings Forecast

Next quarter’s earnings estimate for ANAB is -$1.42 with a range of -$1.95 to -$0.81. The previous quarter’s EPS was -$1.34. ANAB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ANAB has Preformed in-line its overall industry.

ANAB Sales Forecast

Next quarter’s sales forecast for ANAB is $15.85M with a range of $0.00 to $29.00M. The previous quarter’s sales results were $22.26M. ANAB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ANAB has Preformed in-line its overall industry.

ANAB Stock Forecast FAQ

What is ANAB’s average 12-month price target, according to analysts?

Based on analyst ratings, AnaptysBio Inc’s 12-month average price target is 51.29.

What is ANAB’s upside potential, based on the analysts’ average price target?

AnaptysBio Inc has 71.71% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ANAB a Buy, Sell or Hold?

AnaptysBio Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.

What is AnaptysBio Inc’s price target?

The average price target for AnaptysBio Inc is 51.29. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $20.00. The average price target represents 71.71% Increase from the current price of $29.87.

What do analysts say about AnaptysBio Inc?

AnaptysBio Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of ANAB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AnaptysBio (ANAB) Stock Forecast & Price Target

ANAB Analyst Ratings

ANAB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AnaptysBio

ANAB Analyst Recommendation Trends

ANAB Financial Forecast

ANAB Earnings Forecast

ANAB Sales Forecast

ANAB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts